Endres, Dominique
Leypoldt, Frank
Bechter, Karl
Hasan, Alkomiet
Steiner, Johann
Domschke, Katharina
Wandinger, Klaus-Peter
Falkai, Peter
Arolt, Volker
Stich, Oliver
Rauer, Sebastian
Prüss, Harald
van Elst, Ludger Tebartz
Article History
Received: 25 October 2019
Accepted: 8 February 2020
First Online: 12 March 2020
Compliance with ethical standards
:
: DE: None. FL: Consulting/speech fees from Biogen, Grifols, Teva, Roche, Merck, Fresenius. KB: None. AH: Fees for consulting and lectures by Lundbeck, Otsuka, Janssen-Cilag, Roche and Pfizer. He is editor of the WFSBP Schizophrenia Guidelines and coordinator and member of the control group of the S3 Schizophrenia Guidelines. JS: Fees for consulting and lectures within the last 3 years from Janssen-Cilag. KD: Steering Committee Neurosciences, Janssen. KPW: He worked for Euroimmun up to December 2012. He has received payment for a lecture from the laboratory Dr. Fenner and colleagues. PF: Consulting for the past 3 years: Abbott, Janssen, Lundbeck, Otsuka, Recordati, Richter, Servier, Takeda. VA: He has been working as an advisor and gave lectures for the following pharmaceutical companies: Allergan, Astra-Zeneca, Janssen, Neuraxpharm, Otsuka, Organon, Sanofi, Servier, and Tromsdorff. OS: None. SR: Receiving consulting and lecture fees, grant and research support from Bayer Vital, Biogen, Merck Serono, Novartis, Sanofi-Aventis, Genzyme, Roche and Teva. Furthermore, SR indicates that he is a founding executive board member of ravo Diagnostika GmbH Freiburg. HP: None. LTvE: Advisory boards, lectures, or travel grants within the last three years: Roche, Eli Lilly, Janssen-Cilag, Novartis, Shire, UCB, GSK, Servier, Janssen and Cyberonics. Book publications on schizophrenic disorders, autism and “epilepsy and mind”.